Kintara Therapeutics, Inc. (KTRA)
| Market Cap | 36.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.23M |
| Shares Out | 17.11M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.50 |
| Previous Close | $1.50 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.38 |
| Day's Range | 1.34 - 1.59 |
| Day's Volume | 1,133,849 |
| 52-Week Range | 0.38 - 1.72 |
News
SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cance...
SAN DIEGO, Aug. 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has entered into...
SAN DIEGO, Aug. 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has regained co...
About KTRA
Kintara Therapeutics, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast ... [Read more...]
| Industry Biotechnology | Founded 2009 |
| CEO Saiid Zarrabian | Employees 4 |
| Stock Exchange NASDAQ | Ticker Symbol KTRA |